Payment overview · 2025
General Payments
$15.99
1 reported records · 1 companies
Healthcare provider profile · identity verified
John V Allcott, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EUGENE, OR · NPI 1871658153
Verified facts
What the public records show
CMS Open Payments records show John V Allcott, MD received $15.99 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 99 |
| Lisinopril | Lisinopril | 371 | 92 |
| Gabapentin | Gabapentin | 353 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 47 |
| Carvedilol | Carvedilol | 215 | 49 |
| Eliquis | Apixaban | 211 | 40 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 205 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 64 |
| Omeprazole | Omeprazole | 196 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 191 | 25 |
| Trazodone Hcl | Trazodone Hcl | 149 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 140 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 23 |
| Losartan Potassium | Losartan Potassium | 126 | 37 |
| Ibuprofen | Ibuprofen | 111 | 41 |
| Clonidine Hcl | Clonidine Hcl | 110 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 29 |
| Metformin Hcl | Metformin Hcl | 107 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 18 |
| Propranolol Hcl | Propranolol Hcl | 95 | 22 |
| Sertraline Hcl | Sertraline Hcl | 87 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 15 |
| Furosemide | Furosemide | 86 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 14 |
| Pregabalin | Pregabalin | 83 | 16 |
| Prazosin Hcl | Prazosin Hcl | 80 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 24 |
| Valsartan | Valsartan | 80 | 22 |
| Metformin Hcl Er | Metformin Hcl | 74 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 23 |
| Jardiance | Empagliflozin | 67 | 12 |
| Olanzapine | Olanzapine | 67 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 66 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 13 |
| Tramadol Hcl | Tramadol Hcl | 65 | 15 |
| Lamotrigine | Lamotrigine | 63 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Prednisone | Prednisone | 54 | 16 |
| Potassium Chloride | Potassium Chloride | 51 | 11 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Mirtazapine | Mirtazapine | 50 | 12 |
| Simvastatin | Simvastatin | 50 | 11 |
| Zenpep | Lipase/Protease/Amylase | 48 | suppressed |
| Baclofen | Baclofen | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 15 |
| Atenolol | Atenolol | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 11 |
| Finasteride | Finasteride | 43 | 13 |
| Naltrexone Hcl | Naltrexone Hcl | 43 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 13 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 15 |
| Ozempic | Semaglutide | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Estradiol | Estradiol | 27 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | 12 |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 22 | 11 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 11 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Perphenazine | Perphenazine | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.99 · 1 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error